Abstract
UCSF researchers have created a class of reversible, covalent small molecule kinase inhibitors that could be more selective and safer than previous kinase inhibitors. Principia Biopharma has exclusively licensed the technology and hopes to develop new compounds to treat cancer and autoimmune diseases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
